Exosomes are mobile extracellular vesicles with a diameter 40 to 150 nm. They play a critical role in several processes such as the development of cancers, intercellular signaling, drug resistance mechanisms, and cell-to-cell communication by fusion onto the cell membrane of recipient cells. These vesicles contain endogenous proteins and both noncoding and coding RNAs (microRNA and messenger RNAs) that can be delivered to various types of cells. Furthermore, exosomes exist in body fluids such as plasma, cerebrospinal fluid, and urine. Therefore, they could be used as a novel carrier to deliver therapeutic nucleic-acid drugs for cancer therapy. It was recently documented that, hypoxia promotes exosomes secretion in different tumor types leading to the activation of vascular cells and angiogenesis. Cancer cell-derived exosomes (CCEs) have been used as prognostic and diagnostic markers in many types of cancers because exosomes are stable at 4°C and −70°C. CCEs have many functional roles in tumorigenesis, metastasis, and invasion. Consequently, this review presents the data about the therapeutic application of exosomes and the role of CCEs in cancer invasion, drug resistance, and metastasis.
Cardiovascular disease (CVD) is the leading cause of mortality globally. There are few useful markers available for CVD risk stratification that has proven clinical utility. Scavenger receptor B type I (SR‐BI) is a cell surface protein that plays a major role in cholesterol homeostasis through its interaction with high‐density lipoprotein‐cholesterol (HDL‐C) esters (CE). HDL delivers CE to the liver through selective uptake by the SR‐BI. SR‐BI also regulates the inflammatory response. It has been shown that SR‐BI overexpression has beneficial, protective effects in atherogenesis, and there is considerable interest in developing antiatherogenic strategies that involve SR‐BI‐mediated increases in reverse cholesterol transport through HDL and/or low‐density lipoprotein. Further investigations are essential to explore the clinical utility of this approach. Moreover, there is growing evidence showing associations between genetic variants with modulation of SR‐BI function that may, thereby, increase CVD risk. The aim of the current review was to provide an overview of the possible molecular mechanisms by which SR‐BI may affect CVD risk, and the clinical implications of this, with particular emphasis on preclinical studies on genetic changes of SR‐BI and CVD risk.
Since human beings could travel beyond the earth atmosphere, scientists started to investigate the effect of microgravity on human cells. Microgravity has different effects on normal and cancer cells, but the related mechanisms are not well-known till now. The aim of the present review is to focus on the consequences of exposing the cancer cells to reduced gravity. Some cancer cells organize three-dimensional structures under microgravity. Obviously, microgravity is an external stress, which can affect cell proliferation, apoptosis, cytoskeleton and signaling pathways. In addition, it touches immune-related components, regulates immune responses, and implicates immune cell activation. Low mutation aggregation and cancer rate in astronauts may lead to use microgravity as a therapeutic approach. However, it reduces the invasion and migration in some types of cancer cells, triggers the oncogenic signaling pathways including KRAS, and inhibits proliferation in normal lymphocytes. In conclusion, using microgravity as a therapeutic method in cancer treatment needs to be more investigated on both cancer and normal cells, and might not become true in the near future.
Abstract. Background: Vitamin D deficiency (VDD) is a major public health problem. There are few comprehensive systematic reviews about the relationship between Vitamin D status and liver and renal disease in Iran. Methods: We systemically searched the following databases: Web of Science; PubMed; Cochrane Library; Scopus; Science Direct; Google Scholar and two Iranian databases (Scientific Information Database (SID) and IranMedex) up until November 2017 to identify all randomized control trials (RCTs), case control, cross-sectional and cohort studies investigating the association between vitamin D and any form of liver or kidney disease. Results: Vitamin D insufficiency, or deficiency (VDD), is highly prevalent in Iran, reports varying between 44.4% in Isfahan to 98% in Gorgan. There is also a high prevalence of VDD among patients with liver or kidney disease, and the administration of vitamin D supplements may have beneficial effects on lipid profile, blood glucose, liver function and fatty liver disease, and bone health. Low serum vitamin D levels are related with abnormalities in these laboratory and clinical parameters. Conclusion: VDD is prevalent in patients with chronic liver or renal disease in Iran. There appear to be several beneficial effects of vitamin D supplementation in vitamin D deficient patients with liver or kidney disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.